Reports Stack News and Updates
On Friday, Pfizer announced the discontinuation of the development of the twice-daily variant of its experimental weight loss pill. This decision follows a mid-stage clinical study where obese patients experienced substantial weight loss while facing challenges in tolerating the drug. The pharmaceutical company noted elevated rates of adverse side effects, ...
Read More »Pfizer Ceases Production of Dual-Dose Weight Loss Medication Following Elevated Incidence of Adverse Effects
